David E. Mery

Postdoctoral Fellow

UAMS

Also affiliated: Cornell University (2019); Winthrop Rockefeller Foundation (2022–2025)

Postdoc Researcher

7 h-index 32 pubs 192 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

David E. Mery's research focuses on multiple myeloma and its precursor stages, investigating the underlying mechanisms and potential therapeutic targets. His work includes the development of novel CAR-T cell therapies, such as bispecific BCMA/CD24 CAR-T cells, to control tumor growth. Mery also examines the immune microenvironment's alterations in multiple myeloma using multi-omics approaches and investigates the role of specific gene expressions, like NEK2, in suppressing T cell immunity. His research extends to prognostic scoring systems, such as the Myeloma Prognostic Score System (MPSS), and the evaluation of existing risk stratification models in patients undergoing autologous stem cell transplantation. He has contributed to studies exploring the prognostic value of ferritin and the potential of targeting mitochondrial matrix peptidases in high-risk multiple myeloma.

Metrics

h-index: 7
Publications: 32
Citations: 192

Selected Publications

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma (2026)

Blood DOI OpenAlex
Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)

Blood DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

Cancer Biomarkers 1 citation DOI OpenAlex
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025)

Blood 6 citations DOI OpenAlex
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025)

Cell Reports Medicine 4 citations DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

Blood DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

Blood DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

Blood 1 citation DOI OpenAlex
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment (2024)

Blood DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

Blood Cancer Journal 35 citations DOI OpenAlex
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)

Cancers 4 citations DOI OpenAlex
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)

Blood Cancer Journal 7 citations DOI OpenAlex
Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024)

American Journal of Hematology 17 citations DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

Nature Communications 46 citations DOI OpenAlex
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)

Journal of Clinical Investigation 7 citations DOI OpenAlex